These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 34528056)

  • 1. Invited Commentary: Drug Checking for Novel Insights Into the Unregulated Drug Supply.
    Dasgupta N; Figgatt MC
    Am J Epidemiol; 2022 Jan; 191(2):248-252. PubMed ID: 34528056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Motivators of and barriers to drug checking engagement in British Columbia, Canada: Findings from a cross-sectional study.
    Tobias S; Ferguson M; Palis H; Burmeister C; McDougall J; Liu L; Graham B; Ti L; Buxton JA
    Int J Drug Policy; 2024 Jan; 123():104290. PubMed ID: 38101275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond a spec: assessing heterogeneity in the unregulated opioid supply.
    Gozdzialski L; Louw R; Kielty C; Margolese A; Poarch E; Sherman M; Cameron F; Gill C; Wallace B; Hore D
    Harm Reduct J; 2024 Mar; 21(1):63. PubMed ID: 38491435
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Responding to changes in the unregulated drug supply: the need for a dynamic approach to drug checking technologies.
    Bhuiyan I; Tobias S; Ti L
    Am J Drug Alcohol Abuse; 2023 Nov; 49(6):685-690. PubMed ID: 37506334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A qualitative assessment of key considerations for drug checking service implementation.
    Grace Rose C; Pickard AS; Kulbokas V; Hoferka S; Friedman K; Epstein J; Lee TA
    Harm Reduct J; 2023 Oct; 20(1):151. PubMed ID: 37848875
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factors associated with obtaining prescribed safer supply among people accessing harm reduction services: findings from a cross-sectional survey.
    Palis H; Haywood B; McDougall J; Xavier CG; Desai R; Tobias S; Burgess H; Ferguson M; Liu L; Kinniburgh B; Slaunwhite AK; Crabtree A; Buxton JA
    Harm Reduct J; 2024 Jan; 21(1):5. PubMed ID: 38184576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhancing drug checking services for supply monitoring: perspectives on implementation in syringe service programs in the USA.
    Moon KJ; Whitehead HD; Trinh A; Hasenstab KA; Hayes KL; Stanley D; Carter B; Barclay R; Lieberman M; Nawaz S
    Harm Reduct J; 2024 Jan; 21(1):11. PubMed ID: 38218980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A survey of North American drug checking services operating in 2022.
    Park JN; Tardif J; Thompson E; Rosen JG; Lira JAS; Green TC
    Int J Drug Policy; 2023 Nov; 121():104206. PubMed ID: 37797571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Public health impact and harm reduction implications of xylazine-involved overdoses: a narrative review.
    Zhu DT
    Harm Reduct J; 2023 Sep; 20(1):131. PubMed ID: 37700329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from Drug Checking Programs: Practicing Bootstrap Public Health Whilst Tailoring to Local Drug User Needs.
    Ondocsin J; Ciccarone D; Moran L; Outram S; Werb D; Thomas L; Arnold EA
    Int J Environ Res Public Health; 2023 May; 20(11):. PubMed ID: 37297603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adulterants present in the San Diego county fentanyl supply: a laboratory analysis of seized law enforcement samples.
    Galust H; Seltzer JA; Hardin JR; Friedman NA; Salamat J; Clark RF; Harmon J
    BMC Public Health; 2024 Mar; 24(1):923. PubMed ID: 38553721
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First drug-checking study at an electronic festival and fentanyl detection in the central region of Mexico.
    Cruz SL; Bencomo-Cruz M; Medina-Mora ME; Vázquez-Quiroz F; Fleiz-Bautista C
    Harm Reduct J; 2023 Dec; 20(1):174. PubMed ID: 38053148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A qualitative study on perceptions and experiences of overdose among people who smoke drugs in Vancouver, British Columbia.
    Ivsins A; Bonn M; McNeil R; Boyd J; Kerr T
    Drug Alcohol Depend; 2024 May; 258():111275. PubMed ID: 38581922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An urgent need for community lot testing of lateral flow fentanyl test strips marketed for harm reduction in Northern America.
    Lieberman M; Badea A; Desnoyers C; Hayes K; Park JN
    Harm Reduct J; 2024 Jun; 21(1):115. PubMed ID: 38877522
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recommendations from people who use drugs in Philadelphia, PA about structuring point-of-care drug checking.
    Reed MK; Borne E; Esteves Camacho T; Kelly M; Rising KL
    Harm Reduct J; 2024 Jan; 21(1):26. PubMed ID: 38287409
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Toward automated infrared spectral analysis in community drug checking.
    Gozdzialski L; Hutchison A; Wallace B; Gill C; Hore D
    Drug Test Anal; 2024 Jan; 16(1):83-92. PubMed ID: 37248686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Support of Community Drug Checking Programs: Position Statement of AMERSA, Inc. (Association for Multidisciplinary Education and Research in Substance use and Addiction).
    Hill K; Dunham K; Brokos Z; Butner JL; Hull I; Sue KL; Li L; Thakarar K
    Subst Use Addctn J; 2024 Jan; 45(1):4-9. PubMed ID: 38258861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is expected substance type associated with timing of drug checking service utilization?: A cross-sectional study.
    Beaulieu T; Wood E; Tobias S; Lysyshyn M; Patel P; Matthews J; Ti L
    Harm Reduct J; 2021 Jun; 18(1):66. PubMed ID: 34176497
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 'Drug decriminalization' in Canada: a plea for a nuanced, evidence-informed, and realistic approach towards improved health outcomes.
    Fischer B
    Can J Public Health; 2023 Dec; 114(6):943-946. PubMed ID: 37462843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Challenges of implementing safer supply programs in Canada during the COVID-19 pandemic: A qualitative analysis.
    Karamouzian M; Rafat B; Kolla G; Urbanoski K; Atkinson K; Bardwell G; Bonn M; Touesnard N; Henderson N; Bowles J; Boyd J; Brunelle C; Eeuwes J; Fikowski J; Gomes T; Guta A; Hyshka E; Ivsins A; Kennedy MC; Laurence G; Martignetti L; Nafeh F; Salters K; Tu D; Strike C; Pauly B; Werb D
    Int J Drug Policy; 2023 Oct; 120():104157. PubMed ID: 37574645
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.